Celyad SA (CYAD): Price and Financial Metrics
Celyad SA (CYAD)
Today's Latest Price: $10.27 USD
Updated Aug 7 3:49pm
Add CYAD to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
See all "A" rated Strong Buy stocks
CYAD Stock Summary
- With a price/sales ratio of 21,142.51, Celyad Oncology SA has a higher such ratio than 99.93% of stocks in our set.
- With a year-over-year growth in debt of 529.59%, Celyad Oncology SA's debt growth rate surpasses 96.68% of about US stocks.
- Revenue growth over the past 12 months for Celyad Oncology SA comes in at 94.83%, a number that bests 94.06% of the US stocks we're tracking.
- Stocks that are quantitatively similar to CYAD, based on their financial statements, market capitalization, and price volatility, are NK, ADVM, TGTX, URGN, and WKHS.
- CYAD's SEC filings can be seen here. And to visit Celyad Oncology SA's official web site, go to www.celyad.com.
CYAD Stock Price Chart Technical Analysis Charts
CYAD Price/Volume Stats
| Current price | $10.27 | 52-week high | $14.98 |
| Prev. close | $10.15 | 52-week low | $4.10 |
| Day low | $10.23 | Volume | 1,016 |
| Day high | $10.30 | Avg. volume | 19,607 |
| 50-day MA | $10.84 | Dividend yield | N/A |
| 200-day MA | $9.85 | Market Cap | 143.18M |
Celyad SA (CYAD) Company Bio
Celyad SA is a leader in engineered cell therapy treatments with clinical programs initially targeting indications in cardiology and oncology. The company was founded in 2004 and is based in Mont-Saint-Guibert, Belgium.
Loading social stream, please wait...